{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:06:51Z","timestamp":1794103611250,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.vaccine.2020.02.035","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T09:17:44Z","timestamp":1582190264000},"page":"3042-3049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients"],"prefix":"10.1016","volume":"38","author":[{"given":"Sharla L.","family":"McDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Weldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Jorba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olen M.","family":"Kew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Pallansch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara C.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Steven Oberste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.02.035_b0005","series-title":"Vaccines","first-page":"598","article-title":"Poliovirus vaccine\u2014live","author":"Sutter","year":"2013"},{"key":"10.1016\/j.vaccine.2020.02.035_b0010","first-page":"468","article-title":"Progress toward polio eradication \u2014 Worldwide, 2013\u20132014","volume":"63","author":"Moturi","year":"2014","journal-title":"Morbid Mortal Wkly Rep."},{"key":"10.1016\/j.vaccine.2020.02.035_b0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.15585\/mmwr.mm6530a3","article-title":"Update on vaccine-derived polioviruses - worldwide, January 2015-May 2016","volume":"65","author":"Jorba","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2020.02.035_b0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1126\/science.1068284","article-title":"Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus","volume":"296","author":"Kew","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.02.035_b0025","unstructured":"Expanding contributions of the global laboratory network for poliomyelitis eradication, 2000\u20132001. Releve epidemiologique hebdomadaire\/Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations. 2002;77:133\u20137."},{"key":"10.1016\/j.vaccine.2020.02.035_b0030","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijantimicag.2010.11.027","article-title":"Immunoglobulin treatment in primary antibody deficiency","volume":"37","author":"Maarschalk-Ellerbroek","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.vaccine.2020.02.035_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/jinf.2002.1066","article-title":"Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality","volume":"46","author":"Halliday","year":"2003","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2020.02.035_b0040","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/oxfordjournals.aje.a117211","article-title":"Paralytic poliomyelitis in Romania, 1984\u20131992. Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection","volume":"140","author":"Strebel","year":"1994","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0045","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/CVI.00293-12","article-title":"High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies","volume":"19","author":"Driss","year":"2012","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2020.02.035_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005114","article-title":"Twenty-eight years of poliovirus replication in an immunodeficient individual: impact on the global polio eradication initiative","volume":"11","author":"Dunn","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.02.035_b0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biologicals.2004.11.001","article-title":"Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method","volume":"33","author":"Rezapkin","year":"2005","journal-title":"Biol: J Int Assoc Biol Standard"},{"key":"10.1016\/j.vaccine.2020.02.035_b0060","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/JVI.79.2.1062-1070.2005","article-title":"Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine","volume":"79","author":"Cherkasova","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/viro.1999.0003","article-title":"Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient","volume":"265","author":"Bellmunt","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.02.035_b0070","doi-asserted-by":"crossref","first-page":"13839","DOI":"10.1128\/JVI.78.24.13839-13847.2004","article-title":"Long-term excretion of vaccine-derived poliovirus by a healthy child","volume":"78","author":"Martin","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0075","doi-asserted-by":"crossref","first-page":"13512","DOI":"10.1128\/JVI.78.24.13512-13521.2004","article-title":"Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001","volume":"78","author":"Shimizu","year":"2004","journal-title":"J Virol"},{"issue":"Pt 4","key":"10.1016\/j.vaccine.2020.02.035_b0080","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1099\/0022-1317-80-4-907","article-title":"A Sabin vaccine-derived field isolate of poliovirus type 1 displaying aberrant phenotypic and genetic features, including a deletion in antigenic site 1","volume":"80","author":"Mulders","year":"1999","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0085","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1099\/vir.0.18708-0","article-title":"Characterization of a recombinant type 3\/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1","volume":"84","author":"Blomqvist","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0090","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JVI.80.6.2641-2653.2006","article-title":"Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties","volume":"80","author":"Yakovenko","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.vaccine.2010.10.028","article-title":"Determination of antigenic properties of vaccine derived poliovirus strains","volume":"29","author":"Pliaka","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.035_b0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jmv.10224","article-title":"Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan","volume":"68","author":"Horie","year":"2002","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0105","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.inf.0000143641.27336.2e","article-title":"Population immunity to polioviruses among preschool children from four urban underserved low income communities, United States, 1997\u20132001","volume":"23","author":"Prevots","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.035_b0110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4939-3292-4_8","article-title":"Standardized methods for detection of poliovirus antibodies","volume":"1387","author":"Weldon","year":"2016","journal-title":"Methods Mol Biol."},{"key":"10.1016\/j.vaccine.2020.02.035_b0115","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Archiv f experiment Pathol u Pharmakol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0120","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/JVI.02954-12","article-title":"Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria","volume":"87","author":"Burns","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0125","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01949-17","article-title":"Dynamics of evolution of poliovirus neutralizing antigenic sites and other capsid functional domains during a large and prolonged outbreak","author":"Shaw","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0130","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1098\/rstb.1989.0024","article-title":"The antigenic structure of poliovirus","volume":"323","author":"Hogle","year":"1989","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.vaccine.2020.02.035_b0135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/viro.1993.1044","article-title":"Antigenic sites on type 2 poliovirus","volume":"192","author":"Patel","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.02.035_b0140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0042-6822(87)90136-X","article-title":"Reduced mouse neurovirulence of poliovirus type 2 Lansing antigenic variants selected with monoclonal antibodies","volume":"161","author":"La Monica","year":"1987","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.02.035_b0145","first-page":"275","article-title":"The rapid generation of mutation data matrices from protein sequences","volume":"8","author":"Jones","year":"1992","journal-title":"Comput Appl Biosci: CABIOS"},{"key":"10.1016\/j.vaccine.2020.02.035_b0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4049\/jimmunol.74.1.71","article-title":"The effect of gamma globulin on sub clinical infection in familial associates of poliomyelitis cases. II. Serological studies and virus isolations from pharyngeal secretions","volume":"74","author":"Brown","year":"1955","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.biologicals.2006.02.007","article-title":"Vaccine-derived polioviruses","volume":"34","author":"Agol","year":"2006","journal-title":"Biol: J Int Assoc Biol Standard"},{"key":"10.1016\/j.vaccine.2020.02.035_b0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jama.1964.03070140047006","article-title":"Paralytic disease associated with oral polio vaccines","volume":"190","author":"Henderson","year":"1964","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2020.02.035_b0165","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","article-title":"Vaccine-derived polioviruses","volume":"210","author":"Burns","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.035_b0170","series-title":"Polio Eradication and Endgame Strategic Plan 2013\u20132018","author":"Global Polio Eradication Initiative","year":"2013"},{"key":"10.1016\/j.vaccine.2020.02.035_b0175","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/cid\/cix110","article-title":"Immune serum from sabin inactivated poliovirus vaccine immunization neutralizes multiple individual wild and vaccine-derived polioviruses","volume":"64","author":"Sun","year":"2017","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2020.02.035_b0180","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/596052","article-title":"Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota","volume":"199","author":"Alexander","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.035_b0185","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMoa1008677","article-title":"Vaccine-derived poliomyelitis 12 years after infection in Minnesota","volume":"364","author":"DeVries","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.02.035_b0190","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1128\/JVI.78.9.4876-4883.2004","article-title":"Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia","volume":"78","author":"Blomqvist","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0195","first-page":"pii\/19566","article-title":"Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage","volume":"15","author":"Roivainen","year":"2010","journal-title":"Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin."},{"key":"10.1016\/j.vaccine.2020.02.035_b0200","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1128\/JCM.38.10.3729-3734.2000","article-title":"Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel","volume":"38","author":"Shulman","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/protein\/7.1.47","article-title":"The BC loop in poliovirus coat protein VP1: an ideal acceptor site for major insertions","volume":"7","author":"Stirk","year":"1994","journal-title":"Protein Eng"},{"key":"10.1016\/j.vaccine.2020.02.035_b0210","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/596052","article-title":"Transmission of imported vaccine-derived poliovirus in an under-vaccinated community\u2014Minnesota, USA","volume":"199","author":"Alexander","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.035_b0215","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1016\/j.vaccine.2012.10.035","article-title":"Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka","volume":"30","author":"de Silva","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.035_b0220","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1128\/JVI.02553-10","article-title":"Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis","volume":"85","author":"Chen","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.02.035_b0225","first-page":"335","article-title":"Antiviral Activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model","volume":"215","author":"Collett","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.035_b0230","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jcv.2007.04.002","article-title":"Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency","volume":"39","author":"Parvaneh","year":"2007","journal-title":"J Clin Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:58Z","timestamp":1759401718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20302449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":46,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0264410X20302449"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}